Stockholm, Sweden – Barnik Invest Group is pleased to announce the official launch of Cell4Cure AB, a new company focused on developing advanced therapies based on antigen-specific dendritic cell mediated tolerance. This innovative approach aims to treat diseases where the immune system attacks the body’s own tissues.
A consortium of former Idogen board members, together with Barnik Invest Group, have come together to form this exciting new venture.
“We are thrilled to announce the official launch of Cell4Cure AB,” said Hamid Bakhshi, CEO of Barnik Invest Group. “This is a significant milestone in our mission to bring innovative therapies to patients with unmet medical needs. With the acquisition of Idogen’s technology platform, Cell4Cure is well-positioned to develop life-changing treatments for autoimmune diseases.”
Cell4Cure plans to initiate the planning and financing process for the restart of the Toler8 clinical trial, a Phase I/II study aimed at inducing tolerance for Factor VIII treatment in Hemophilia A. This study will prioritize safety and the evaluation of tolerance induction.
For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: hamid.bakhshi@barnikinvest.com
About Barnik Invest Group
Barnik Invest Group is a leading 360 solution partner for small Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully-owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development and commercialization solutions. Barnik’s mission is to nurture promising life science companies from early clinical development phase to commercialization, enabling them to achieve positive cash flows or successful exits and ultimately enhancing patient well-being and improving human health worldwide. For more information visit www.barnikinvest.com.
